Effects of Combined Exercise on the Risk of Arteriosclerosis in Sedentary Postmenopausal Women
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 113
- 试验地点
- 1
- 主要终点
- Flow mediated dilation (FMD)
研究概览
简要总结
This study investigated the effects of three exercise modalities: aerobic exercise, resistance exercise, and combined exercise on the risk of arteriosclerosis in sedentary postmenopausal women.
详细描述
This study aims to compare the effects of different kinds of exercise on the risk of arteriosclerosis in sedentary postmenopausal women. Participants were recruited and randomly assigned to aerobic exercise, resistance exercise, combined exercise or control group. The intervention lasted for 12 weeks. Endothelial function indicators, chronic inflammation indicators, arteriosclerosis related indicators, blood pressure indicators were assessed before and after the intervention.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 45 Years 至 69 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Participants have been postmenopausal for more than 12 months and have not received any exogenous estrogen supplementation after menopause.
- •Participants were screened using the International Physical Activity Questionnaire-Short Form (IPAQ-S), with a physical activity level classified as "low." They must not have engaged in moderate-intensity physical activity for at least 3 days per week, with a duration of no less than 30 minutes per day, for over 3 consecutive months.
- •Participants were screened using the Physical Activity Readiness Questionnaire+ (PAR-Q+) and be deemed safe to undergo further intervention.
排除标准
- •Participants with acute or chronic musculoskeletal disorders, cardiovascular diseases, or similar conditions.
- •Participants with abnormal blood pressure: resting systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg, or those taking antihypertensive medications.
- •Participants with abnormally high arterial stiffness (within pathological range): brachial-ankle pulse wave velocity (baPWV) >1800 cm/s.
- •Participants recently taken medications that may affect blood indicators, such as hormones or anti-inflammatory drugs.
- •Participants with unstable body weight in the past 3 months (fluctuation greater than ±2.5 kg).
- •Participants currently participating in other intervention studies or those with regular exercise habits in daily life.
- •Participants who smoke or consume alcohol regularly.
研究组 & 干预措施
AE group
干预措施: AE group (Behavioral)
RE group
干预措施: RE group (Behavioral)
CE group
干预措施: CE group (Behavioral)
CON group
干预措施: ON group (Behavioral)
结局指标
主要结局
Flow mediated dilation (FMD)
时间窗: 12 weeks
The change of flow mediated dilation before and after intervention.
Brachial ankle pulse wave velocity (baPWV)
时间窗: 12 weeks
The change of baPWV before and after intervention.
Ankle brachial index (ABI)
时间窗: 12 weeks
The change of ABI before and after intervention.
Carotid intima-media thickness (cIMT)
时间窗: 12 weeks
The change of cIMT before and after intervention.
Systolic blood pressure (SBP)
时间窗: 12 weeks
The change of SBP before and after intervention.
Diastolic blood pressure (DBP)
时间窗: 12 weeks
The change of DBP before and after intervention.
Peak systolic velocity (PSV)
时间窗: 12 weeks
The change of PSV of carotid artery before and after intervention.
End diastolic velocity (EDV)
时间窗: 12 weeks
The change of EDV of carotid artery before and after intervention.
Pulsatility index (PI)
时间窗: 12 weeks
The change of PI of carotid artery before and after intervention.
Resistance index (RI)
时间窗: 12 weeks
The change of RI of carotid artery before and after intervention.
Wall Shear Stress (WSS)
时间窗: 12 weeks
The change of WSS of carotid artery before and after intervention.
次要结局
- Nitric oxide (NO)(12 weeks)
- Prostacyclin (PGI2)(12 weeks)
- Endothelin-1 (ET-1)(12 weeks)
- Angiotensin II (AngII)(12 weeks)
- C-Reactive protein (CRP)(12 weeks)
- Interleukin-6 (IL-6)(12 weeks)
- Estrogen(12 weeks)
- Soluble intercellular adhesion molecule-1(sICAM-1)(12 weeks)
- Soluble vascular cell adhesion molecule-1 (sVCAM-1)(12 weeks)
- Total Cholesterol (TC)(12 weeks)
- High-density lipoprotein cholesterol (HDL-C)(12 weeks)
- Low-density lipoprotein cholesterol (LDL-C)(12 weeks)
- Left ventricular posterior wall thickness at end-diastole (LVPWd)(12 weeks)
- Left ventricular posterior wall thickness at end-systole (LVPWs)(12 weeks)
- Stroke volume (SV)(12 weeks)
- Heart rate (HR)(12 weeks)
- Left ventricular ejection fraction (LVEF)(12 weeks)
- Cardiac output (CO)(12 weeks)
- Endothelial Nitric Oxide Synthase (eNOS)(12 weeks)
- Maximal oxygen uptake (VO2max)(12 weeks)
- Body mass index (BMI)(12 weeks)
- Body fat weight(12 weeks)
- Body fat%(12 weeks)
- Pittsburgh sleep quality index (PSQI)(12 weeks)
- Food frequency questionnaire (FFQ)(12 weeks)
- Cluster of Differentiation 14 (CD14) mRNA and Protein Expression(12 weeks)
- Mitogen-activated protein kinase 14 (MAPK14) mRNA(12 weeks)
- p38 Mitogen-activated protein kinase (p38 MAPK) Protein Expression(12 weeks)
- Tetraspanin 4 (TSPAN4) mRNA and Protein Expression(12 weeks)
- Nitric Oxide Synthase 3 (NOS3) mRNA and Protein Expression(12 weeks)